NRXPW — NRX Pharmaceuticals, Inc. — Income statement
From the XBRL facts of the company's SEC filings. USD, millions, except per-share figures. Latest filing read: 2026-11-16.
Annual · Quarterly | Latest filing · As first reported | Download all statements (Excel)
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | TTM Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 0.0 | 1.2 | 4.3‡ |
| Total revenues | - | - | - | - | 0.0 | 1.2 | 4.3‡ |
| Cost of revenues | - | - | - | - | 0.0 | 0.5 | 2.6‡ |
| Gross profit | - | - | - | - | 0.0‡ | 0.7‡ | 1.7‡ |
| Selling, general and administrative | 11.4‡ | 74.9‡ | 27.3‡ | 14.2‡ | 13.5 | 13.1 | 19.7‡ |
| R&D expenses | 10.6 | 20.3 | 17.0 | 13.4 | 6.2 | 3.8 | 5.8‡ |
| Other operating expenses, total | 29.3‡ | 20.6‡ | 0.0‡ | 0.3‡ | (1.2)‡ | 0.1‡ | 0.3‡ |
| Operating income (GAAP, as reported) | (51.4) | (115.8) | (44.3) | (27.8) | (18.5) | (16.2) | (24.0)‡ |
| Operating income excl. unusual items (S&P method) | (51.4)‡ | (115.8)‡ | (44.3)‡ | (27.6)‡ | (19.7)‡ | (16.2)‡ | - |
| Interest expense | 0.1 | 0.0 | - | 0.1 | 0.2 | 0.7 | 1.4‡ |
| Interest and investment income | - | - | 0.2 | 0.5 | 0.0 | 0.0 | 0.0‡ |
| Net interest expenses | 0.1 | 0.0‡ | 0.2‡ | 0.4‡ | (0.2)‡ | (0.7)‡ | (1.4)‡ |
| Other non-operating income (expenses) | (0.5)‡ | 22.8‡ | 4.3‡ | (2.7)‡ | (6.4)‡ | (11.7)‡ | 5.6‡ |
| Total unusual items | 0.4‡ | 0.1‡ | - | (0.3)‡ | 1.2‡ | (1.3)‡ | 0.0‡ |
| EBT excl. unusual items | (52.1)‡ | (93.2)‡ | (39.8)‡ | - | - | - | - |
| EBT incl. unusual items | (51.8) | (93.1) | (39.8) | - | - | - | - |
| Income tax expense | 0.0 | - | - | - | - | - | - |
| Earnings from continuing operations | (51.8)‡ | - | - | - | - | - | - |
| Net income to company | - | (93.1) | (39.8) | (30.2) | - | - | - |
| Minority interest | - | 0.0‡ | 0.0‡ | 0.0‡ | - | - | - |
| Net income | (51.8) | (93.1) | (39.8) | (30.2) | (25.1) | (28.6) | (19.8)‡ |
| NI to common incl. extra items | (51.8) | (348.9) | (39.8) | (30.2) | (25.1) | (28.6)‡ | (19.8)‡ |
| NI to common excl. extra items | (51.8)‡ | (348.9)‡ | (39.8)‡ | (30.2)‡ | (25.1)‡ | (28.6)‡ | (19.8)‡ |
| Revenue per share | - | - | - | - | 0.00‡ | 0.06‡ | 0.12‡ |
| Basic EPS | (1.51) | (1.98) | (0.60) | (3.98) | (2.36) | (1.34) | (0.56)‡ |
| Basic EPS, continuing operations | (1.51) | (7.44) | (0.60) | - | - | - | - |
| Basic weighted average shares | 34.3 | 46.9 | 65.8 | 7.6 | 10.6 | 21.4 | 35.5‡ |
| Diluted EPS | (1.51) | (1.98) | (0.60) | - | - | - | - |
| Diluted EPS, continuing operations | (1.51) | (7.44) | (0.60) | - | - | - | - |
| Diluted weighted average shares | 34.3 | 46.9 | 65.8 | - | - | - | - |
| Normalized net income (S&P method, 37.5 %) | (32.6)‡ | (58.2)‡ | (24.8)‡ | - | - | - | - |
| Normalized basic EPS (S&P method) | (0.95)‡ | (1.24)‡ | (0.38)‡ | - | - | - | - |
| Normalized diluted EPS (S&P method) | (0.95)‡ | (1.24)‡ | (0.38)‡ | - | - | - | - |
| EBITDA | (51.4)‡ | (115.8)‡ | (44.3)‡ | (27.8)‡ | (18.5)‡ | (16.2)‡ | (23.8)‡ |
| EBIT | (51.4)‡ | (115.8)‡ | (44.3)‡ | (27.8)‡ | (18.5)‡ | (16.2)‡ | (24.0)‡ |
| Effective tax rate | NM | - | - | - | - | - | - |
‡ derived by arithmetic from reported figures (a fourth quarter is the year less nine months). † read from a substitute line. § reported in a note, not on the face of the statement. “-” not reported. NM not meaningful. Normalized rows follow the S&P method: pre-tax income excluding unusual items, a flat 37.5 % tax rate, less minority interest.
By product or service
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | TTM Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Procedures | - | - | - | - | - | 0.4 | - |
| Therapy | - | - | - | - | - | 0.9 | - |
Segment figures as the company tagged them in its filings, one breakdown per table; members need not sum to the total.